{"id":25413,"date":"2022-09-27T17:40:00","date_gmt":"2022-09-27T09:40:00","guid":{"rendered":"https:\/\/flcube.com\/?p=25413"},"modified":"2025-02-04T17:42:43","modified_gmt":"2025-02-04T09:42:43","slug":"yichang-hec-reports-strong-recovery-in-2022-interim-results","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=25413","title":{"rendered":"YiChang HEC Reports Strong Recovery in 2022 Interim Results"},"content":{"rendered":"\n<p>China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/1558:HKG\">HKG: 1558<\/a>) has released its 2022 interim report, showcasing a significant recovery. The company generated RMB 1.293 billion ($180.7 million) in revenues during the first half of 2022, up 539.5% year-on-year (YOY), and RMB 961 million ($134.3 million) in gross profits, up 853.1% YOY. The main driver of this recovery was the easing of COVID-19 lockdowns in southern provinces, which led to a resurgence of influenza, a key market for HEC.<\/p>\n\n\n\n<p><strong>Product Sales and Approvals<\/strong><br>During the period, oseltamivir accounted for 77.8% of total sales, with other key products including benzbromarone (3.0%), telmisartan (2.4%), olmesartan medoxomil (1.9%), and moxifloxacin (1.2%). Additionally, the company received marketing approval for metoprolol, a hypertension and heart failure drug, and the antibiotic azithromycin.<\/p>\n\n\n\n<p><strong>R&amp;D and Future Outlook<\/strong><br>Research and development (R&amp;D) costs were RMB 40.91 million ($5.7 million), down 17.6% YOY. HEC is strategically pivoting towards endocrine and metabolic disease areas, particularly diabetes. The company has received marketing approval for recombinant human insulin injection and insulin glargine injection, with insulin aspart injection, insulin aspart 30 injection, and protamine recombinant human insulin injection (premix 30R) awaiting regulatory decisions. Phase III clinical studies for rongliflozin and liraglutide are also underway.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has released its 2022 interim report,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[30,27,2358,859],"class_list":["post-25413","post","type-post","status-publish","format-standard","hentry","category-company","tag-biotech","tag-finanical-reports","tag-hec-changjiang-pharmaceutical","tag-hkg-1558"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>YiChang HEC Reports Strong Recovery in 2022 Interim Results - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has released its 2022 interim report, showcasing a significant recovery. The company generated RMB 1.293 billion ($180.7 million) in revenues during the first half of 2022, up 539.5% year-on-year (YOY), and RMB 961 million ($134.3 million) in gross profits, up 853.1% YOY. The main driver of this recovery was the easing of COVID-19 lockdowns in southern provinces, which led to a resurgence of influenza, a key market for HEC.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=25413\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"YiChang HEC Reports Strong Recovery in 2022 Interim Results\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=25413\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-27T09:40:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-04T09:42:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25413#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25413\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"YiChang HEC Reports Strong Recovery in 2022 Interim Results\",\"datePublished\":\"2022-09-27T09:40:00+00:00\",\"dateModified\":\"2025-02-04T09:42:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25413\"},\"wordCount\":198,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Finanical Reports\",\"HEC ChangJiang Pharmaceutical\",\"HKG: 1558\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25413#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25413\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=25413\",\"name\":\"YiChang HEC Reports Strong Recovery in 2022 Interim Results - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-09-27T09:40:00+00:00\",\"dateModified\":\"2025-02-04T09:42:43+00:00\",\"description\":\"China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has released its 2022 interim report, showcasing a significant recovery. The company generated RMB 1.293 billion ($180.7 million) in revenues during the first half of 2022, up 539.5% year-on-year (YOY), and RMB 961 million ($134.3 million) in gross profits, up 853.1% YOY. The main driver of this recovery was the easing of COVID-19 lockdowns in southern provinces, which led to a resurgence of influenza, a key market for HEC.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25413#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25413\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25413#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"YiChang HEC Reports Strong Recovery in 2022 Interim Results\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"YiChang HEC Reports Strong Recovery in 2022 Interim Results - Insight, China&#039;s Pharmaceutical Industry","description":"China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has released its 2022 interim report, showcasing a significant recovery. The company generated RMB 1.293 billion ($180.7 million) in revenues during the first half of 2022, up 539.5% year-on-year (YOY), and RMB 961 million ($134.3 million) in gross profits, up 853.1% YOY. The main driver of this recovery was the easing of COVID-19 lockdowns in southern provinces, which led to a resurgence of influenza, a key market for HEC.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=25413","og_locale":"en_US","og_type":"article","og_title":"YiChang HEC Reports Strong Recovery in 2022 Interim Results","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=25413","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-09-27T09:40:00+00:00","article_modified_time":"2025-02-04T09:42:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=25413#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=25413"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"YiChang HEC Reports Strong Recovery in 2022 Interim Results","datePublished":"2022-09-27T09:40:00+00:00","dateModified":"2025-02-04T09:42:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=25413"},"wordCount":198,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Finanical Reports","HEC ChangJiang Pharmaceutical","HKG: 1558"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=25413#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=25413","url":"https:\/\/flcube.com\/?p=25413","name":"YiChang HEC Reports Strong Recovery in 2022 Interim Results - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-09-27T09:40:00+00:00","dateModified":"2025-02-04T09:42:43+00:00","description":"China-based YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558) has released its 2022 interim report, showcasing a significant recovery. The company generated RMB 1.293 billion ($180.7 million) in revenues during the first half of 2022, up 539.5% year-on-year (YOY), and RMB 961 million ($134.3 million) in gross profits, up 853.1% YOY. The main driver of this recovery was the easing of COVID-19 lockdowns in southern provinces, which led to a resurgence of influenza, a key market for HEC.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=25413#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=25413"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=25413#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"YiChang HEC Reports Strong Recovery in 2022 Interim Results"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25413","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25413"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25413\/revisions"}],"predecessor-version":[{"id":25414,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25413\/revisions\/25414"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25413"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25413"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}